The policy lists multiple uses of G‑CSF and GM‑CSF that Aetna considers experimental or investigational because effectiveness for these indications has not been established. Examples include: assisted reproductive technology (e.g., IVF), autoimmune neutropenia (pegfilgrastim note), cancer‑related fatigue, chemosensitization of myeloid leukemias, many non‑neutropenia inflammatory or neurologic disorders (ALS, stroke, spinal cord injury), diabetic foot infections, Crohn’s disease, prostate cancer, recurrent miscarriage/implantation failure, and routine use with most chemotherapy regimens as prophylaxis. The policy specifically states that administration of pegfilgrastim formulations (Neulasta, Fulphila, Udenyca) with weekly chemotherapy regimens is considered experimental/investigational and may be denied.

Requests should document absence of known hypersensitivity to product components. Members with known hypersensitivity to E. coli‑derived proteins, filgrastim, filgrastim biosimilars, pegfilgrastim or any component of the product are listed as contraindicated and such history is a basis for denying coverage.

Granix (tbo‑filgrastim) and Leukine (sargramostim) have usage cautions and labeled limits: Granix is indicated to reduce duration of severe neutropenia when administered per label (usual starting dose 5 mcg/kg/day), and the policy emphasizes that routine prophylactic use of Granix in regimens without significant FN risk or in members not receiving myelosuppressive chemotherapy may be denied. Leukine carries hematologic and safety dose‑modification recommendations and the label warns against use in patients with excessive leukemic myeloid blasts (≥10%); severe allergic reactions require immediate discontinuation.

The policy excludes routine use in myeloid malignancies (e.g., AML, CML) and in myelodysplastic syndromes unless specific compendial indications apply. For pegfilgrastim, pediatric use is limited: pegfilgrastim should not be used in infants, children, or smaller adolescents weighing 45 kg unless dosing is per prescribing information; pediatric dosing references in product labels must be followed.

The document summarizes randomized trials and meta‑analyses showing limited or inconsistent benefit of CSFs/GM‑CSF in many non‑oncologic settings. Cochrane and meta‑analyses in stroke and sepsis found no clear mortality benefit and mixed functional outcomes, and neonatal prophylactic GM‑CSF trials did not reduce sepsis or improve survival. These safety and evidence limitations support excluding routine use outside established oncology indications.

The prescribing information and product labels note that serious allergic reactions to pegfilgrastim or filgrastim products are contraindications. The policy reiterates that a documented history of a serious allergic reaction to pegfilgrastim or filgrastim (or other human G‑CSFs) precludes use of these agents.

Several pegfilgrastim biosimilars are not indicated for PBPC mobilization. The policy highlights that products such as Udenyca and Ziextenzo (and other listed biosimilars) lack an approved indication for mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation; requests for mobilization with these biosimilars must be reviewed against labeled indications and may be denied if an approved mobilization agent is required.

Per product labeling, pegfilgrastim, eflapegrastim, and filgrastim products are contraindicated in patients with prior serious allergic reactions to human G‑CSFs (including eflapegrastim, pegfilgrastim, filgrastim). Such a history should be documented and will preclude use.

Product warnings and the policy advise caution or avoidance in patients at risk for specific serious adverse events: splenic rupture (evaluate left upper quadrant/shoulder pain), acute respiratory distress syndrome (ARDS) (discontinue for new respiratory failure), sickle cell crises in patients with sickle cell disease, glomerulonephritis (monitor renal signs and consider dose reduction/discontinuation if suspected), marked leukocytosis (monitor CBC and hold therapy if WBC >20,000/mm3), and capillary leak syndrome. Leukine also includes immediate discontinuation for severe allergic/anaphylactic reactions.

UpToDate reviews cited in the policy do not endorse routine G‑CSF use for certain non‑oncology contexts. For example, an UpToDate review on noninfectious lung transplant complications does not list G‑CSF as a management tool, and UpToDate on immune neutropenia does not describe pegfilgrastim as a standard therapeutic option; these references support non‑routine use in these settings.

The reference sections included in the document do not themselves list additional explicit exclusion criteria beyond those summarized in the policy text; no separate exclusion list is provided in these reference‑only chunks.

The policy identifies that use of CSFs in afebrile neutropenic patients and routine prophylactic use in most chemotherapy regimens are considered not appropriate or experimental/investigational. The policy explicitly lists neutropenic members who are afebrile among indications judged investigational and notes routine prophylaxis across most regimens is not supported.

The policy states that routine prophylactic CSF use is not medically necessary for chemotherapy regimens that do not carry a clinically significant risk of febrile neutropenia. CSFs are recommended when the expected incidence of FN is greater than 20% or for selected patients with intermediate‑risk regimens plus patient risk factors; otherwise routine prophylaxis is not appropriate.

Granix (tbo‑filgrastim) labeling and the policy reiterate that routine prophylactic use of Granix in regimens without a significant risk of febrile neutropenia or in patients not receiving myelosuppressive chemotherapy is not appropriate and may be denied.

Across multiple sections the policy emphasizes that CSFs are not routinely indicated when the regimen's FN risk is not clinically significant; prophylactic administration is reserved for high‑risk regimens (FN risk >20%) or intermediate risk with additional patient risk factors.

The policy summarizes neonatal evidence: randomized trials and meta‑analyses of prophylactic GM‑CSF in extremely pre‑term neonates corrected neutropenia but did not reduce sepsis or improve survival. On that basis, prophylactic GM‑CSF for preventing sepsis or improving survival in extremely pre‑term neonates is considered not medically necessary.

The document reports multiple small trials and systematic reviews of G‑CSF/GM‑CSF in non‑oncologic indications (stroke, peripheral artery disease, assisted reproduction, diabetic foot infection, spinal cord injury). Evidence is inconsistent or limited: some trials show physiologic effects or secondary outcome signals but overall clinical benefit is not established, and these uses remain investigational or unsupported for routine coverage.

Evidence and guideline statements indicate that routine post‑hematopoietic cell transplant use of growth factors is controversial. Randomized trials and guidelines show CSFs shorten neutropenia duration (≈1 day in some analyses) and may reduce infection risk, but have not demonstrated clear mortality benefit; therefore routine use after HCT is not universally recommended and should be considered selectively for defined patient groups.

Multiple small randomized trials and systematic reviews evaluated G‑CSF for assisted reproduction. While some studies report improvements in surrogate measures (e.g., endometrial thickness) or select subgroup pregnancy rates, pooled evidence is inconsistent and of low quality; routine use of G‑CSF to improve pregnancy or live‑birth rates is not supported by consistent evidence.

The document's reference lists provide trial and guideline citations but do not add explicit additional 'not medically necessary' statements beyond those contained in the policy text; the references support the policy's clinical positions.

Colony‑stimulating factors (G‑CSF and GM‑CSF) stimulate proliferation, differentiation and activation of myeloid progenitors leading to increased neutrophil production and mobilization of CD34+ hematopoietic stem cells. Clinically, G‑CSFs reduce the duration and severity of chemotherapy‑induced neutropenia, decrease febrile neutropenia incidence in high‑risk settings, and are used to mobilize peripheral blood progenitor cells for collection. GM‑CSF has overlapping biologic effects and has been studied as an immunotherapy adjuvant and for post‑transplant myeloid recovery, but evidence for non‑oncologic benefits is limited.

The policy summarizes evidence‑limited contexts where trials or meta‑analyses show no definitive clinical benefit: G‑CSF/GM‑CSF in stroke trials and stroke meta‑analyses demonstrated safety but no clear functional benefit; Cochrane and other reviews show inconsistent or negative results for many non‑oncologic indications, informing the policy's exclusion of those uses from routine coverage.

Trials of prophylactic GM‑CSF in extremely pre‑term neonates increased neutrophil counts but did not reduce sepsis or improve survival; meta‑analysis evidence showed no survival benefit, supporting the policy statement that such prophylactic GM‑CSF use is not medically necessary.

G‑CSF is defined as a cytokine that stimulates neutrophil production and mobilizes CD34+ hematopoietic stem cells; its clinical rationale is to reduce duration of neutropenia and FN in patients receiving myelosuppressive chemotherapy, and to enable PBPC mobilization for transplantation. Product labels and trials support these roles.

GM‑CSF (sargramostim) is a cytokine that stimulates proliferation and differentiation of granulocyte and macrophage progenitors and has been studied as an immunotherapy adjunct and for accelerating myeloid recovery after transplant or AML induction; however, non‑oncologic indications have limited evidence and remain investigational.

Same‑day pegfilgrastim administration is noted as a logistic alternative in some guidelines, but trial evidence shows same‑day dosing can be associated with a longer duration of grade‑4 neutropenia and higher febrile neutropenia incidence compared with next‑day administration. The policy therefore prefers administration ≥24 hours after chemotherapy while allowing same‑day use only under specific logistical circumstances with supporting rationale.

Pivotal randomized evidence (for example tbo‑filgrastim trials) demonstrated reduced duration of severe neutropenia versus placebo in advanced breast cancer and underpins approval and coverage for prophylaxis in non‑myeloid malignancies when criteria are met; such trial data are cited to support coverage in labeled contexts.

Pegfilgrastim randomized trials defined febrile neutropenia endpoints (e.g., temperature ≥ 38.2°C with ANC ≤ 0.5 x 10^9/L) and demonstrated substantial reductions in FN incidence and hospitalizations versus placebo (Study 3: FN 1% vs 17%), supporting the clinical rationale for prophylactic pegfilgrastim in high‑risk chemotherapy regimens.

Rolvedon (eflapegrastim) pivotal trials (ADVANCE/RECOVER) used endpoints including duration of severe neutropenia (DSN), time to ANC recovery, and incidence of febrile neutropenia. Rolvedon met noninferiority (and showed small superiority in cycle‑1 DSN) versus pegfilgrastim at a lower G‑CSF dose, providing evidence for its approved indication to reduce FN incidence.

Prescribing information for multiple originator and biosimilar products (e.g., Udenyca, Ziextenzo, Fulphila, Nyvepria) are cited throughout the policy; these references are the basis for product‑specific labeling, dosing, indications, contraindications, and safety warnings that inform coverage decisions and required documentation.

Operational prior authorization details are described in the Clinical Policy Bulletin, but specific plan prior‑auth procedures and code lists are not provided in these reference chunks; providers are instructed to follow Aetna's authorization processes and submit required clinical documentation per the bulletin.